About

Sean P. Nolan is an Independent Director of Ventas (since 2019) and a member of the Compensation Committee and the Nominating, Governance and Corporate Responsibility Committee. He brings 35 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur.

Mr. Nolan previously served as CEO of AveXis, which he grew from four employees to a fully integrated global public company that was ultimately sold to Novartis for $8.7 billion.

Roles

Ventas, Inc.
Independent Director · Current role
2019–present
Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
Chief Executive Officer (since 2022); Chairman of the Board (since 2020)
—
Nolan Capital, LLC
President · An investment fund (since 2019).
—
AveXis, Inc. (formerly NASDAQ: AVXS)
President and Chief Executive Officer · Gene therapy company sold to Novartis for $8.7 billion.
2015-2018
InterMune, Inc. (formerly NASDAQ: ITMN)
Chief Business Officer · Biopharmaceutical company.
2013-2015
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Chief Commercial Officer · Pharmaceuticals company.
2011-2012
Lundbeck, Inc.
Chief Commercial Officer and President · U.S. affiliate of H. Lundbeck A/S, a Danish pharmaceuticals company.
2009-2010

External Roles

Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
Director / Chairman of the Board
—
Neoleukin Therapeutics (now Neurogene, Inc.) (NASDAQ: NLTX)
Director
2019-2020
Aquinox Pharmaceuticals, Inc. (formerly NASDAQ: AQXP)
Director
2015-2019

Director Compensation

FY 2025
Fees earned or paid in cash
$145,000
Stock awards
$185,000
Total
$330,000

Also at Ventas, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.